Skip to main content
. 2019 Jan 15;92(3):e244–e252. doi: 10.1212/WNL.0000000000006783

Figure 2. Impact of first- and second-line therapies on NEOS score.

Figure 2

(A) Distribution of NEOS scores in patients who received only first-line therapies and in patients who received second-line therapies. There is a shift toward higher NEOS scores in patients who received second-line therapies. (B) Relationship between NEOS score and probability of good functional status at 1 year is similar in patients who received only first-line therapies compared to those who received second-line therapies. NEOS = anti-NMDAR Encephalitis One-Year Functional Status.